Marius Ilié Laboratory of Clinical and Experimental Pathology, Centre Hospitalier Universitaire de Nice Université Côte d’Azur, CHU de Nice Biography Publications Institution JoVE Articles Marius Ilié has not added a biography. If you are Marius Ilié and would like to personalize this page please email our Author Liaison for assistance. Publications The Need to Set Up a Biobank Dedicated to Lymphoid Malignancies: Experience of a Single Center (Laboratory of Clinical and Experimental Pathology, University Côte D'Azur, Nice, France) Journal of Personalized Medicine. Jun, 2023 | Pubmed ID: 37511690 Cholesterol Efflux Pathways Hinder KRAS-driven Lung Tumor Progenitor Cell Expansion Cell Stem Cell. Jun, 2023 | Pubmed ID: 37267915 Analytical Validation of Automated Multiplex Chromogenic Immunohistochemistry for Diagnostic and Predictive Purpose in Non-small Cell Lung Cancer Lung Cancer (Amsterdam, Netherlands). Apr, 2022 | Pubmed ID: 35134710 Salivary Detection of COVID-19: Clinical Performance of Oral Sponge Sampling for SARS-CoV-2 Testing ERJ Open Research. Oct, 2021 | Pubmed ID: 34877351 A Rapid Near-patient RT-PCR Test for Suspected COVID-19: a Study of the Diagnostic Accuracy Annals of Translational Medicine. Jun, 2021 | Pubmed ID: 34350236 Critical Assessment in Routine Clinical Practice of Liquid Biopsy for EGFR Status Testing in Non-Small-Cell Lung Cancer: A Single-Laboratory Experience (LPCE, Nice, France) Clinical Lung Cancer. Jan, 2020 | Pubmed ID: 31519454 "Interchangeability" of PD-L1 Immunohistochemistry Assays: a Meta-analysis of Diagnostic Accuracy Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc. Jan, 2020 | Pubmed ID: 31383961 [Pseudo-tumor Lesions Induced by Infectious Agents. Case No. 4] Annales De Pathologie. Aug, 2019 | Pubmed ID: 31104854 [Pseudo Tumor Lesions Induced by Infectious Agents. Case No. 3] Annales De Pathologie. Aug, 2019 | Pubmed ID: 31010595 [Recent Updates Regarding PD-L1 Testing in Non-small Cell Lung Carcinoma] Annales De Pathologie. Aug, 2019 | Pubmed ID: 30853496 Multiplexed Immunohistochemistry for Molecular and Immune Profiling in Lung Cancer-Just About Ready for Prime-Time? Cancers. Feb, 2019 | Pubmed ID: 30818873 Circulating Tumor Cell Detection in Lung Cancer: But to What End? Cancers. Feb, 2019 | Pubmed ID: 30813420 The OncoAge Consortium: Linking Aging and Oncology from Bench to Bedside and Back Again Cancers. Feb, 2019 | Pubmed ID: 30795607 [The Age of Artificial Intelligence in Lung Cancer Pathology: Between Hope, Gloom and Perspectives] Annales De Pathologie. Apr, 2019 | Pubmed ID: 30772062 Automated Chromogenic Multiplexed Immunohistochemistry Assay for Diagnosis and Predictive Biomarker Testing in Non-small Cell Lung Cancer Lung Cancer (Amsterdam, Netherlands). Oct, 2018 | Pubmed ID: 30268486 Dermoscopy of Eccrine Angiomatous Hamartoma: The Spitzoid Pattern JAAD Case Reports. Sep, 2018 | Pubmed ID: 30238051 Chromogenic Multiplex Immunohistochemistry Reveals Modulation of the Immune Microenvironment Associated with Survival in Elderly Patients with Lung Adenocarcinoma Cancers. Sep, 2018 | Pubmed ID: 30216999 Establishing a Dedicated Lung Cancer Biobank at the University Center Hospital of Nice (France). Why and How? Cancers. Jun, 2018 | Pubmed ID: 29966305 [Carcinoma of Unknown Primary. Case No. 7] Annales De Pathologie. Jun, 2018 | Pubmed ID: 29929748 [Carcinoma of Unknown Primary. Role of the Pathologist in 2018: Introduction] Annales De Pathologie. Jun, 2018 | Pubmed ID: 29929740 Ensuring the Safety and Security of Frozen Lung Cancer Tissue Collections Through the Encapsulation of Dried DNA Cancers. Jun, 2018 | Pubmed ID: 29891792 Effect of Mutant Variants of the KRAS Gene on PD-L1 Expression and on the Immune Microenvironment and Association with Clinical Outcome in Lung Adenocarcinoma Patients Lung Cancer (Amsterdam, Netherlands). Jul, 2018 | Pubmed ID: 29858030 Immunohistochemistry for Diagnosis of Metastatic Carcinomas of Unknown Primary Site Cancers. Apr, 2018 | Pubmed ID: 29621151 Rapid Decay of Engulfed Extracellular MiRNA by XRN1 Exonuclease Promotes Transient Epithelial-mesenchymal Transition Nucleic Acids Research. Apr, 2018 | Pubmed ID: 29562367 Use of the Ion PGM and the GeneReader NGS Systems in Daily Routine Practice for Advanced Lung Adenocarcinoma Patients: A Practical Point of View Reporting a Comparative Study and Assessment of 90 Patients Cancers. Mar, 2018 | Pubmed ID: 29561830 Any Place for Immunohistochemistry Within the Predictive Biomarkers of Treatment in Lung Cancer Patients? Cancers. Mar, 2018 | Pubmed ID: 29534030 Use of Circulating Tumor Cells in Prospective Clinical Trials for NSCLC Patients - Standardization of the Pre-analytical Conditions Clinical Chemistry and Laboratory Medicine. May, 2018 | Pubmed ID: 29397019 Reproducibility of PD-L1 Assessment in Non-small Cell Lung Cancer-know Your Limits but Never Stop Trying to Exceed Them Translational Lung Cancer Research. Dec, 2017 | Pubmed ID: 29299411 Circulating Tumour Cells As a Potential Screening Tool for Lung Cancer (the AIR Study): Protocol of a Prospective Multicentre Cohort Study in France BMJ Open. 12, 2017 | Pubmed ID: 29282271 Atezolizumab in Advanced Non-small Cell Lung Cancer Journal of Thoracic Disease. Oct, 2017 | Pubmed ID: 29268352 Response to First Line Chemotherapy Regimen is Associated with Efficacy of Nivolumab in Non-small-cell Lung Cancer Oncoimmunology. 2017 | Pubmed ID: 28932641 MiR-223-3p Inhibits Angiogenesis and Promotes Resistance to Cetuximab in Head and Neck Squamous Cell Carcinoma Oncotarget. Aug, 2017 | Pubmed ID: 28915663 Use of the 22C3 Anti-PD-L1 Antibody to Determine PD-L1 Expression in Multiple Automated Immunohistochemistry Platforms PloS One. 2017 | Pubmed ID: 28797130 Annales De Pathologie. Aug, 2017 | Pubmed ID: 28778623 Expression of MET in Circulating Tumor Cells Correlates with Expression in Tumor Tissue from Advanced-stage Lung Cancer Patients Oncotarget. Apr, 2017 | Pubmed ID: 28212540 [PD1/PD-L1 Immunohistochemistry in Thoracic Oncology: Where Are We?] Annales De Pathologie. Feb, 2017 | Pubmed ID: 28159404 Fibronectin-guided Migration of Carcinoma Collectives Nature Communications. Jan, 2017 | Pubmed ID: 28102238 Rapid Decay of Engulfed Extracellular MiRNA by XRN1 Exonuclease Promotes Transient Epithelial-mesenchymal Transition Nucleic Acids Research. Apr, 2017 | Pubmed ID: 27994032 Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer Christophe Bontoux1,2,3,4,5, Virginie Lespinet-Fabre1,2,3,4, Olivier Bordone1,2,3,4, Virginie Tanga1,2,3,4, Maryline Allegra1,2,3,4, Myriam Salah1,2,3,4, Salomé Lalvée1,2,3,4, Samantha Goffinet1,2,3,4, Jonathan Benzaquen3,4,5,6, Charles-Hugo Marquette3,4,5,6, Marius Ilié1,2,3,4,5, Véronique Hofman1,2,3,4,5, Paul Hofman1,2,3,4,5 1Laboratory of Clinical and Experimental Pathology, Centre Hospitalier Universitaire de Nice, Université Côte d’Azur, CHU de Nice, 2Hospital-Integrated Biobank (BB-0033-00025), Université Côte d'Azur, Hôpital Pasteur, CHU de Nice, 3Institut Hospitalo-Universitaire (IHU), RespirERA, Université Côte d'Azur, Hôpital Pasteur, CHU de Nice, 4FHU OncoAge, Université Côte d'Azur, 5Team 4, Institute of Research on Cancer and Aging (IRCAN), CNRS INSERM, Centre Antoine-Lacassagne, Université Côte d'Azur, 6Department of Pulmonary Medicine and Thoracic Oncology, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur JoVE 65190 Biology Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients Marius Ilié1,2,3, Mélanie Ngo-Mai1, Elodie Long-Mira1,2, Sandra Lassalle1,2, Catherine Butori1, Coraline Bence1, Marame Hamila1, Véronique Hofman1,2,3, Paul Hofman1,2,3 1Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Hospital University Federation OncoAge, Université Côte d’Azur, 2Institute for Research on Cancer and Aging in Nice (Inserm U1081 and CNRS 7284), Université Côte d’Azur, 3Hospital-Integrated Biobank (BB-0033-00025), Pasteur Hospital, Université Côte d’Azur JoVE 58082 Cancer Research
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer Christophe Bontoux1,2,3,4,5, Virginie Lespinet-Fabre1,2,3,4, Olivier Bordone1,2,3,4, Virginie Tanga1,2,3,4, Maryline Allegra1,2,3,4, Myriam Salah1,2,3,4, Salomé Lalvée1,2,3,4, Samantha Goffinet1,2,3,4, Jonathan Benzaquen3,4,5,6, Charles-Hugo Marquette3,4,5,6, Marius Ilié1,2,3,4,5, Véronique Hofman1,2,3,4,5, Paul Hofman1,2,3,4,5 1Laboratory of Clinical and Experimental Pathology, Centre Hospitalier Universitaire de Nice, Université Côte d’Azur, CHU de Nice, 2Hospital-Integrated Biobank (BB-0033-00025), Université Côte d'Azur, Hôpital Pasteur, CHU de Nice, 3Institut Hospitalo-Universitaire (IHU), RespirERA, Université Côte d'Azur, Hôpital Pasteur, CHU de Nice, 4FHU OncoAge, Université Côte d'Azur, 5Team 4, Institute of Research on Cancer and Aging (IRCAN), CNRS INSERM, Centre Antoine-Lacassagne, Université Côte d'Azur, 6Department of Pulmonary Medicine and Thoracic Oncology, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur JoVE 65190 Biology
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients Marius Ilié1,2,3, Mélanie Ngo-Mai1, Elodie Long-Mira1,2, Sandra Lassalle1,2, Catherine Butori1, Coraline Bence1, Marame Hamila1, Véronique Hofman1,2,3, Paul Hofman1,2,3 1Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Hospital University Federation OncoAge, Université Côte d’Azur, 2Institute for Research on Cancer and Aging in Nice (Inserm U1081 and CNRS 7284), Université Côte d’Azur, 3Hospital-Integrated Biobank (BB-0033-00025), Pasteur Hospital, Université Côte d’Azur JoVE 58082 Cancer Research
